Christopher Downs
Equibles does not estimate personal net worth.
Get an email with a short summary when CNS Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get CNSP alertsAbout Christopher Downs
CNS Pharmaceuticals, Inc. reported in an 8-K filed February 17, 2026 that Christopher Downs resigned as Chief Financial Officer, effective March 2, 2026. CNS Pharmaceuticals, Inc. reported in an 8-K filed February 17, 2026 that Christopher Downs was appointed Senior Vice President – Finance, effective March 2, 2026. The proxy statement of CNS Pharmaceuticals, Inc. reports total compensation of $728,809 for Christopher Downs in fiscal 2025, including a base salary of $450,000. Disclosed compensation is on record for 7 fiscal years. CNS Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at CNS Pharmaceuticals, Inc. includes Rami Levin (CEO and Board Member), Faith Charles (Chairman and Board Member), Steve O'Loughlin (CFO) and 7 others.
“Christopher Downs, the Company’s current Chief Financial Officer, pursuant to which Mr. Downs agreed to resign as Chief Financial Officer effective March 2, 2026 and to serve as the Company’s Senior Vice President – Finance effective March 2, 2026.”
“Christopher Downs, the Company’s current Chief Financial Officer, pursuant to which Mr. Downs agreed to resign as Chief Financial Officer effective March 2, 2026 and to serve as the Company’s Senior Vice President – Finance effective March 2, 2026.”
Affiliation history
-
CNS Pharmaceuticals, Inc. (CNSP)
SEC 8-K
Current2026-03-02–present
Company network
Leadership on record at CNS Pharmaceuticals, Inc.
- Rami Levin CEO, Board Member
- Faith Charles Chairman, Board Member
- Steve O'Loughlin CFO
- Eric Faulkner CTO
- Amy Mahery Board Member
- Bettina Cockroft Board Member
- Bettina M. Cockroft, M.D., M.B.A. Board Member
- Faith L. Charles Board Member
- Jeff Keyes Board Member
- Jeffrey Keyes Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | CNS Pharmaceuticals, Inc. (CNSP) | Senior Vice President – Finance, (Former Chief Financial Officer) | $450,000 | $728,809 |
| 2024 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $340,000 | $621,050 |
| 2023 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $340,000 | $401,515 |
| 2022 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $340,000 | $481,224 |
| 2021 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $340,000 | $480,475 |
| 2020 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $300,000 | $790,999 |
| 2019 | CNS Pharmaceuticals, Inc. (CNSP) | Chief Financial Officer | $40,000 | $1,154,115 |